Narváez Javier
Servicio de Reumatología, Hospital Universitario de Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España.
Med Clin (Barc). 2020 Dec 11;155(11):494-501. doi: 10.1016/j.medcli.2020.05.009. Epub 2020 Jun 23.
Systemic lupus erythematosus (SLE) is a complex autoimmune multisystemic disease of great clinical heterogeneity and significant potential morbidity and mortality. Although the outlook for patients with SLE has greatly improved, many unmet needs remain. In this review we aim to summarize the most relevant data on SLE that have emerged in recent years. In particular we discuss the new classification criteria from the European League Against Rheumatism and American College of Rheumatology, new biomarkers, novel definitions of remission and low lupus disease activity and what has emerged on new drugs and new therapeutic strategies.
系统性红斑狼疮（SLE）是一种复杂的自身免疫性多系统疾病，具有极大的临床异质性以及显著的潜在发病率和死亡率。尽管SLE患者的预后已大为改善，但仍存在许多未满足的需求。在本综述中，我们旨在总结近年来出现的关于SLE的最相关数据。特别是，我们讨论了欧洲抗风湿病联盟和美国风湿病学会的新分类标准、新的生物标志物、缓解和低狼疮疾病活动的新定义，以及新药和新治疗策略方面的新进展。
